Semaglutide Users Have 27% Lower Medical Costs Than Non-Users in Overweight Patients with Multiple Conditions
Real-world claims data shows semaglutide users with overweight/obesity and multiple complications had 27% lower total medical costs than matched non-users.
Quick Facts
What This Study Found
Semaglutide users with overweight/obesity and multimorbidity had 27% lower total medical costs ($891 vs $1,213/month) compared to matched non-users.
Key Numbers
How They Did This
Retrospective propensity score-matched cohort study using Komodo Health claims database; patients with overweight/obesity and ≥2 obesity-related complications.
Why This Research Matters
Demonstrating cost savings strengthens the economic case for insurance coverage of obesity medications, which remains a major access barrier.
The Bigger Picture
The cost-effectiveness argument may be what ultimately expands insurance coverage of GLP-1 RAs for obesity — showing they save money, not just improve health.
What This Study Doesn't Tell Us
Short follow-up (101 days); medication costs not included in comparison; healthy user bias possible despite matching; retrospective design.
Questions This Raises
- ?Do cost savings persist or increase over longer treatment periods?
- ?Does the cost benefit hold when medication costs are included in total healthcare spending?
Trust & Context
- Key Stat:
- 27% lower medical costs $891 vs $1,213 per patient per month for semaglutide users vs. non-users
- Evidence Grade:
- Retrospective propensity-matched claims analysis — strong for health economics but short follow-up and potential residual confounding.
- Study Age:
- Published 2026 in Expert Review of Pharmacoeconomics & Outcomes Research.
- Original Title:
- Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.
- Published In:
- Expert review of pharmacoeconomics & outcomes research, 26(2), 289-301 (2026)
- Authors:
- Arora, Prachi(2), Dabbous, Firas(2), Udayachalerm, Sariya, Saiontz-Martinez, Cynthia, Zhao, Zhenxiang, O Hartaigh, Briain, Fabricatore, Anthony, Bassan, Matthew, Alvarez, Sara, Fitch, Angela
- Database ID:
- RPEP-14789
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide save money overall?
This study found semaglutide users had 27% lower medical costs, but medication costs were not included. The total economic picture depends on drug pricing and duration of use.
Why does this matter for insurance coverage?
If semaglutide reduces overall medical costs by preventing expensive complications, insurers may find it cost-effective to cover, potentially expanding access for patients.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14789APA
Arora, Prachi; Dabbous, Firas; Udayachalerm, Sariya; Saiontz-Martinez, Cynthia; Zhao, Zhenxiang; O Hartaigh, Briain; Fabricatore, Anthony; Bassan, Matthew; Alvarez, Sara; Fitch, Angela. (2026). Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.. Expert review of pharmacoeconomics & outcomes research, 26(2), 289-301. https://doi.org/10.1080/14737167.2025.2610206
MLA
Arora, Prachi, et al. "Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.." Expert review of pharmacoeconomics & outcomes research, 2026. https://doi.org/10.1080/14737167.2025.2610206
RethinkPeptides
RethinkPeptides Research Database. "Real-world healthcare resource utilization and medical costs..." RPEP-14789. Retrieved from https://rethinkpeptides.com/research/arora-2026-realworld-healthcare-resource-utilization
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.